Comparison of tocilizumab as monotherapy or with add-on disease-modifying antirheumatic drugs in patients with rheumatoid arthritis and inadequate responses to previous treatments: an open-label study close to clinical practice (vol 34, pg 563, 2015)

被引：0
|
作者：
Bykerk, Vivian P. [1 ,2 ]
Oestoer, Andrew J. K. [3 ]
Alvaro-Gracia, Jose [4 ]
Pavelka, Karel [5 ]
Roman Ivorra, Jose Andres [6 ]
Graninger, Winfried [7 ]
Bensen, William [8 ]
Nurmohamed, Michael T. [9 ]
Krause, Andreas [10 ]
Bernasconi, Corrado [11 ]
Aassi, Maher [11 ]
Sibilia, Jean [12 ]
机构：
[1] Hosp Special Surg, Inflammatory Arthrit Ctr, New York, NY 10021 USA
[2] Mt Sinai Hosp, Dept Rheumatol, Toronto, ON M5G 1X5, Canada
[3] Univ Cambridge, Cambridge, England
[4] Hosp Univ Princesa, IIS Princesa, Madrid, Spain
[5] Inst Rheumatol, Prague, Czech Republic
[6] Hosp Univ La Fe, Valencia, Spain
[7] Med Univ Graz, Graz, Austria
[8] McMaster Univ, St Josephs Hosp, Hamilton, ON, Canada
[9] Vrije Univ Amsterdam, Med Ctr, Amsterdam, Netherlands
[10] Immanuel Hosp, Berlin, Germany
[11] F Hoffmann La Roche, Basel, Switzerland
[12] CHU Hautepierre, F-67098 Strasbourg, France
来源：
CLINICAL RHEUMATOLOGY | 2015年 / 34卷 / 07期
关键词：
D O I：
10.1007/s10067-015-2932-z
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1321 / 1321
页数：1
相关论文
共 39 条
  • [1] Comparison of tocilizumab as monotherapy or with add-on disease-modifying antirheumatic drugs in patients with rheumatoid arthritis and inadequate responses to previous treatments: an open-label study close to clinical practice
    Bykerk, Vivian P.
    Oestoer, Andrew J. K.
    Alvaro-Gracia, Jose
    Pavelka, Karel
    Roman Ivorra, Jose Andres
    Graninger, Winfried
    Bensen, William
    Nurmohamed, Michael T.
    Krause, Andreas
    Bernasconi, Corrado
    Aassi, Maher
    Sibilia, Jean
    CLINICAL RHEUMATOLOGY, 2015, 34 (03) : 563 - 571
  • [2] Comparison of tocilizumab as monotherapy or with add-on disease-modifying antirheumatic drugs in patients with rheumatoid arthritis and inadequate responses to previous treatments: an open-label study close to clinical practice
    Vivian P. Bykerk
    Andrew J. K. Östör
    José Alvaro-Gracia
    Karel Pavelka
    José Andrés Román Ivorra
    Winfried Graninger
    William Bensen
    Michael T. Nurmohamed
    Andreas Krause
    Corrado Bernasconi
    Maher Aassi
    Jean Sibilia
    Clinical Rheumatology, 2015, 34 : 563 - 571
  • [3] Erratum to: Comparison of tocilizumab as monotherapy or with add-on disease-modifying antirheumatic drugs in patients with rheumatoid arthritis and inadequate responses to previous treatments: an open-label study close to clinical practice
    Vivian P. Bykerk
    Andrew J. K. Östör
    José Alvaro-Gracia
    Karel Pavelka
    José Andrés Román Ivorra
    Winfried Graninger
    William Bensen
    Michael T. Nurmohamed
    Andreas Krause
    Corrado Bernasconi
    Maher Aassi
    Jean Sibilia
    Clinical Rheumatology, 2015, 34 : 1321 - 1321
  • [4] Comparison of Tocilizumab As Monotherapy or with Add-on Disease-Modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis and An Inadequate Response to Previous Treatments.
    Bykerk, Vivian
    Oestoer, Andrew
    Roman Ivorra, Jose Andres
    Wollenhaupt, Juergen
    Stancati, Andrea
    Bernasconi, Corrado
    Sibilia, Jean
    ARTHRITIS AND RHEUMATISM, 2011, 63 (10): : S866 - S867
  • [5] TOCILIZUMAB AS MONOTHERAPY OR WITH ADD-ON DISEASE-MODIFYING DRUGS IN RHEUMATOID ARTHRITIS PATIENTS WITH INADEQUATE RESPONSE TO PREVIOUS TREATMENTS
    Bykerk, Vivian
    Ostor, Andrew J.
    Roman Ivorra, Jose
    Wollenhaupt, Jurgen
    Stancati, Andrea
    Bernasconi, Corrado
    Sibilia, Jean
    RHEUMATOLOGY, 2012, 51 : 135 - 135
  • [6] COMPARISON OF TOCILIZUMAB AS MONOTHERAPY OR WITH ADD-ON DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS IN PATIENTS WITH RHEUMATOID ARTHRITIS AND AN INADEQUATE RESPONSE TO PREVIOUS TREATMENTS
    Tymms, K.
    Littlejohn, G.
    Bossingham, D.
    Griffiths, H.
    Bagga, H.
    Clemens, L.
    Smith, M.
    Bird, P.
    Mpofu, C.
    Bernasconi, C.
    Bykerk, V.
    INTERNAL MEDICINE JOURNAL, 2012, 42 : 13 - 14
  • [7] Tocilizumab in patients with active rheumatoid arthritis and inadequate response to disease-modifying antirheumatic drugs or tumor necrosis factor inhibitors: subanalysis of Spanish results of an open-label study close to clinical practice
    Alvaro-Gracia, Jose M.
    Fernandez-Nebro, Antonio
    Garcia-Lopez, Alicia
    Guzman, Manuel
    Blanco, Francisco J.
    Navarro, Francisco J.
    Bustabad, Sagrario
    Armendariz, Yolanda
    Roman-Ivorra, Jose A.
    REUMATOLOGIA CLINICA, 2014, 10 (02): : 94 - 100
  • [8] Tocilizumab as Monotherapy or in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs: Twenty-Four-Week Results of an Open-Label, Clinical Practice Study
    Weinblatt, Michael E.
    Kremer, Joel
    Cush, John
    Rigby, William
    Teng, Lichen L.
    Devenport, Jenny
    Singh, Natasha
    Lepley, Denise
    Genovese, Mark C.
    ARTHRITIS CARE & RESEARCH, 2013, 65 (03) : 362 - 371
  • [9] Efficacy of tocilizumab in patients with moderate to severe active rheumatoid arthritis and a previous inadequate response to disease-modifying antirheumatic drugs: the ROSE study
    Yazici, Yusuf
    Curtis, Jeffrey R.
    Ince, Akgun
    Baraf, Herbert
    Malamet, Raymond L.
    Teng, Lichen L.
    Kavanaugh, Arthur
    ANNALS OF THE RHEUMATIC DISEASES, 2012, 71 (02) : 198 - 205
  • [10] Indirect Comparison of Tocilizumab and Other Biologic Agents in Patients with Rheumatoid Arthritis and Inadequate Response to Disease-Modifying Antirheumatic Drugs
    Bergman, Gert J. D.
    Hochberg, Marc C.
    Boers, Maarten
    Wintfeld, Neil
    Kielhorn, Adrian
    Jansen, Jeroen P.
    SEMINARS IN ARTHRITIS AND RHEUMATISM, 2010, 39 (06) : 425 - 441
1234